James F. Nelson

Nature · 2009

⊕ Preprint · OA

Rapamycin fed late in life extends lifespan in genetically heterogeneous mice

▲ 3,824

The Journals of Gerontology Series A · 2010

⊕ Open access · OA

Rapamycin, But Not Resveratrol or Simvastatin, Extends Life Span of Genetically Heterogeneous Mice

▲ 921

Aging Cell · 2013

⊕ Open access · CC-BY

Rapamycin‐mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction

▲ 650

Aging Cell · 2013

⊕ Open access · CC-BY

Acarbose, 17‐α‐estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males

▲ 478

Aging Cell · 2016

⊕ Open access · CC-BY

Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer

▲ 387

Aging Cell · 2008

⊕ Open access · OA

Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice

▲ 362

Aging Cell · 2007

⊕ Open access · OA

An aging Interventions Testing Program: study design and interim report

▲ 233

AGE · 2008

⊕ Open access · OA

Design of aging intervention studies: the NIA interventions testing program

▲ 158

Aging Cell · 2019

⊕ Open access · CC-BY

Acarbose improves health and lifespan in aging HET3 mice

▲ 147

JCI Insight · 2020

⊕ Open access · CC-BY

Canagliflozin extends life span in genetically heterogeneous male but not female mice

▲ 128

Aging Cell · 2011

⊕ Open access · OA

Fat maintenance is a predictor of the murine lifespan response to dietary restriction

▲ 124

Aging Cell · 2021

⊕ Open access · CC-BY

17‐a‐estradiol late in life extends lifespan in aging UM‐HET3 male mice; nicotinamide riboside and three other drugs do not affect lifespan in either sex

▲ 122

Aging Cell · 2019

⊕ Open access · CC-BY

Glycine supplementation extends lifespan of male and female mice

▲ 99

Science · 2022

⊕ Preprint · OA

Sex- and age-dependent genetics of longevity in a heterogeneous mouse population

▲ 83

The Journals of Gerontology Series A · 2001

⊕ Open access · OA

Neuroendocrine and Pharmacological Manipulations to Assess How Caloric Restriction Increases Life Span

▲ 79

Aging Cell · 2022

⊕ Open access · CC-BY

Lifespan benefits for the combination of rapamycin plus acarbose and for captopril in genetically heterogeneous mice

▲ 75

GeroScience · 2023

⊕ Open access · CC-BY

Astaxanthin and meclizine extend lifespan in UM-HET3 male mice; fisetin, SG1002 (hydrogen sulfide donor), dimethyl fumarate, mycophenolic acid, and 4-phenylbutyrate do not significantly affect lifespan in either sex at the doses and schedules used

▲ 56

Experimental Gerontology · 2013

⊕ Preprint · OA

Genetic variation in responses to dietary restriction — An unbiased tool for hypothesis testing

▲ 38

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 2018

⊕ Open access · OA

Genetic cartography of longevity in humans and mice: Current landscape and horizons

▲ 37

GeroScience · 2024

⊕ Preprint · OA

Lifespan effects in male UM-HET3 mice treated with sodium thiosulfate, 16-hydroxyestriol, and late-start canagliflozin

▲ 28

bioRxiv (Cold Spring Harbor Laboratory) · 2020

⊕ Preprint · OA

Canagliflozin Extends Lifespan in Genetically Heterogeneous Male But Not Female Mice

▲ 12

GeroScience · 2024

⊕ Open access · CC-BY

The Gehan test identifies life-extending compounds overlooked by the log-rank test in the NIA Interventions Testing Program: Metformin, Enalapril, caffeic acid phenethyl ester, green tea extract, and 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride

▲ 11

GeroScience · 2025

⊕ Open access · CC-BY

Extension of lifespan by epicatechin, halofuginone and mitoglitazone in male but not female genetically heterogeneous mice

▲ 5

Nature Communications · 2025

⊕ Open access · CC-BY

Deciphering the timing and impact of life-extending interventions: temporal efficacy profiler distinguishes early, midlife, and senescence phase efficacies

▲ 5

bioRxiv (Cold Spring Harbor Laboratory) · 2024

⊕ Preprint · CC-BY

Deciphering the Timing and Impact of Life-extending Interventions: Temporal Efficacy Profiler Distinguishes Early, Midlife, and Senescence Phase Efficacies

▲ 2

The Journals of Gerontology Series A · 2025

⊕ Open access · OA

Sex as a major determinant of pro-longevity drug efficacy: a review of two decades of the NIA Interventions Testing Program

▲ 2

bioRxiv (Cold Spring Harbor Laboratory) · 2025

⊕ Preprint · CC-BY

Genetic Modulation of Lifespan: Dynamic Effects, Sex Differences, and Body Weight Trade-offs

▲ 1